Work Packages

SUMMIT has established an integrated framework of expertise involving ni-neteen European academic institutions, one SME (small and medium sized enterprises) along with six Pharma partners. The team combines compe-tencies from a wide range of disciplines including molecular and cellular biology, genetics, animal models, bioinformatics and imaging technologies.

     Retinopathy                   Nephropathy           Cardiovascular Disease

MISSION

T​o DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:

​

  • the identification of patients at high risk of diabetes complications

  • the monitoring of the complications' progression and patients‘ response to therapy 

​

To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.



Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.

Related Sites